Patients with COVID-19 and non–COVID-19 ARDS exhibit high plasma levels of BM fragment endostatin, which contributes to endothelial barrier disruption in vitro, thereby potentially aggravating immune cell activation and migration (58). This evidence concerns the gene COL18A1 and COVID-19.